Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments.
Rostami E, Bakhshandeh M, Ghaffari-Nazari H, Alinezhad M, Alimohammadi M, Alimohammadi R, Mahmoodi Chalbatani G, Hejazi E, Webster TJ, Tavakkol-Afshari J, Jalali SA. Rostami E, et al. Among authors: alimohammadi r. PLoS One. 2022 Aug 26;17(8):e0273547. doi: 10.1371/journal.pone.0273547. eCollection 2022. PLoS One. 2022. PMID: 36018888 Free PMC article.
Radiotherapy Combination: Insight from Tumor Immune Microenvironment (TIME).
Alimohammadi M, Ghaffari-Nazari H, Alimohammadi R, Bakhshandeh M, Jalali SA, Rezaei N. Alimohammadi M, et al. Among authors: alimohammadi r. Avicenna J Med Biotechnol. 2023 Oct-Dec;15(4):209-215. doi: 10.18502/ajmb.v15i4.13490. Avicenna J Med Biotechnol. 2023. PMID: 38078341 Free PMC article. Review.
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Salehi M, Alavi Darazam I, Nematollahi A, Alimohammadi M, Pouya S, Alimohammadi R, Khajavirad N, Porgoo M, Sedghi M, Mahdi Sepahi M, Azimi M, Hosseini H, Mahmoud Hashemi S, Dehghanizadeh S, Khoddami V. Salehi M, et al. Among authors: alimohammadi r. Int Immunopharmacol. 2024 Jun 15;134:112192. doi: 10.1016/j.intimp.2024.112192. Epub 2024 May 17. Int Immunopharmacol. 2024. PMID: 38761778 Clinical Trial.
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates.
Alimohammadi R, Porgoo M, Eftekhary M, Kiaie SH, Ansari Dezfouli E, Dehghani M, Nasrollahi K, Malekshahabi T, Heidari M, Pouya S, Alimohammadi M, Sattari Khavas D, Modaresi MS, Ghasemi MH, Ramyar H, Mohammadipour F, Hamzelouei F, Mofayezi A, Mottaghi SS, Rahmati A, Razzaznian M, Tirandazi V, Tat M, Borzouee F, Sadeghi H, Haji Mohammadi M, Rastegar L, Safar Sajadi SM, Ehsanbakhsh H, Bazmbar H, Baghernejadan Z, Shams Nouraei M, Pazooki P, Pahlavanneshan M, Alishah K, Nasiri F, Mokhberian N, Mohammadi SS, Akar S, Niknam H, Azizi M, Ajoudanian M, Moteallehi-Ardakani MH, Mousavi Shaegh SA, Ramezani R, Salimi V, Moazzami R, Hashemi SM, Dehghanizadeh S, Khoddami V. Alimohammadi R, et al. NPJ Vaccines. 2022 Sep 2;7(1):105. doi: 10.1038/s41541-022-00528-3. NPJ Vaccines. 2022. PMID: 36056015 Free PMC article.
16 results